TCRX
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
TScan Therapeutics, Inc. (TCRX) is rated D (1.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Revisions (F). The rating has held at D for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | B- (3.0) | D (1.3) | C- (2.1) | F (0.4) | F (0.0) | D (1.4) |
| 2026-11-08 | B- (3.0) | D (1.2) | C- (2.0) | F (0.4) | F (0.0) | D (1.3) |
| 2026-11-01 | B- (3.0) | D (1.2) | C- (2.1) | F (0.4) | F (0.0) | D (1.3) |
| 2026-10-25 | B- (3.0) | D (1.2) | C- (2.1) | F (0.5) | F (0.0) | D (1.3) |
| 2026-10-18 | B- (3.0) | D (1.2) | C- (2.1) | F (0.5) | F (0.0) | D (1.3) |